Navigation Links
New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace

e deaths among women than all other causes of maternal mortality combined and is the leading infectious cause of death in people with HIV/AIDS. The global economic toll of TB is at least $12 billion each year. The bacteria that cause TB, known as Mycobacterium tuberculosis (M.tb), can reside latent in the human body for many years, but once active, attack the respiratory system, and are easily spread through the air like the common cold -- by coughing and sneezing. The WHO estimates that one third of the world is infected with M.tb.

The last class of TB drugs was developed and approved in the 1960s, and the lengthy treatment (6-9 months) required by the old regimen is hindering the progress of TB control. Public health experts agree that a faster-acting TB cure would improve compliance, lower relapse rates, reduce the growth of drug resistant TB, reduce health care costs and save millions of lives. Novel new TB drugs also are needed to be compatible with antiretroviral drugs used to treat HIV for the rising number of those co-infected with TB and HIV, as well as to work against the deadly climb in drug resistant TB.

About the Global Alliance for TB Drug Development

The Global Alliance for TB Drug Development (TB Alliance) is a not-for- profit, product development partnership accelerating the discovery and/or development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection.

Working with public and private partners worldwide, the TB Alliance is leading the development of the most comprehensive portfolio of TB drug candidates in history, and is committed to ensuring that approved new regimens are affordable, adopted and available to those who need them.

The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid, th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/21/2014)... 2014  eRelevance Corporation ( www.erelevancecorp.com ), a ... it has completed integration with Nextech, a popular ... and Dermatology practices. "Integration allows our ... practices using Nextech," stated Bob Fabbio , ... from the EMR we are able to automatically ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... /PRNewswire-iReach/ -- Inc. magazine today ranked ... straight year, No. 349 in Health on its ... the nation,s fastest-growing private companies. The list represents ... segment of the economy—America,s independent entrepreneurs. Companies such ... Zillow, and many other well-known names gained early ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... CARLSBAD, Calif., Oct. 18 Excaliard Pharmaceuticals, Inc. ... as Chairman of its Board of Directors. Mr. ... years of experience in successfully developing and commercializing ... field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company ...
... Bend Research Inc. ( www.bendres.com ), a ... announced today it has extended its drug discovery ... Company ( www.bms.com ) (NYSE: BMY ... Under the terms of the 3-year agreement, Bristol-Myers ...
Cached Medicine Technology:Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board 2Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb 2
(Date:8/22/2014)... first time an oncogenic somatic mutation at amino acid ... been identified in small cell lung cancer (SCLC) tumors ... lines produced increased intracellular signaling and cell growth. , ... representing 15% of all lung cancers and is strongly ... cancer, has been extensively examined for genomic alterations and ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Back-to-school time provides an opportunity ... into the family schedules, an expert suggests. "Forget ... year can also be the start of a new ... professor of kinesiology at the University of the Sciences ... With kids, extracurricular activities likely to build up, "it,s ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... night, Oklahoma Governor Brad Henry vetoed Oklahoma House Bill ... business to conduct research that would kill a human ... risk of death or injury. The Oklahoma House ... Senate failed to follow suit.The bill would have banned ...
... Washington G-2 Reports releases top-10 trends to watch ... Demand for outpatient diagnostic imaging has never ... increase over the next three years. In fact, ... increase by double digits across all modalities (CT, ...
... can help physicians objectively assess a patient,s breast density ... changes that may suggest cancer, according to a study ... of Maryland School of Medicine, Baltimore, MD. ... estimates mammographic breast density. Results obtained by the computer ...
... (VQ) as an alternative to CT for the diagnosis ... patient exposure, according to a study performed at Albert ... NY. "VQ scanning is a nuclear test which shows ... is a pulmonary embolism, the air can enter normally, ...
... breeding techniques, shed light on human genome , , THURSDAY, April ... researchers in 25 countries has succeeded in sequencing the entire ... implications for understanding the biology of this bovine and related ... said the authors of two reports in the April 24 ...
... USA applauds President Obama,s national call for volunteerism and urges ... their local communities. President Obama recently signed a new ... learn about volunteer and service opportunities. "We need your service ... not going to tell you what your role should be. ...
Cached Medicine News:Health News:Demand for Outpatient Diagnostic Imaging Forecast to Increase by Double Digits Across All Modalities Through 2012 2Health News:New computer algorithm helps physicians determine and monitor breast density 2Health News:Scientists From 25 Countries Sequence Cow Genome 2Health News:Scientists From 25 Countries Sequence Cow Genome 3Health News:YWCA USA Applauds President Obama's National Call for Volunteer Service 2
Used to introduce large devices for vascular intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
Medicine Products: